Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 491

Document Document Title
WO/2017/172612A1
Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liq...  
WO/2017/146440A1
The present invention relates to co-crystals of androstenone and vanillin, a method for preparing the same and a use of the same. The co-crystals of androstenone and vanillin of the present invention have a rigid lattice structure so as ...  
WO/2016/154203A1
Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2. In one embodiment, a cytotoxic compound...  
WO/2016/082789A1
Described herein are neuroactive steroids of the Formula (II) : or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and ----- are as defined herein. Such compounds are envisioned, in certain...  
WO/2016/054280A1
A method of preparing a thioic acid intermediate of fluticasone propionate includes: treating a 17β-[(N,N-dimethyl carbamoyl)thio]carbonyl compound in a solution including an alcohol and an alkali metal hydroxide, an alkaline-earth meta...  
WO/2015/010054A3
Described herein are neuroactive steroids of the Formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GAB...  
WO/2014/169833A9
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplate...  
WO/2014/169833A1
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplate...  
WO/2013/002592A3
The present invention relates to a method for purifying high-purity betulonic acid, a method for preparing a piperazine betulonic acid amide derivative using high-purity betulonic acid and a derivative thereof, and a method for purifying...  
WO/2012/161559A2
The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-densit...  
WO/2012/160338A1
The present invention relates to a method of preparing an organic biologically active compound of formula (I), wherein R1, R2, R3, R4,. X1, X2 and X3 are as defined in the specification, to certain novel intermediates obtainable from suc...  
WO/2012/161559A3
The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-densit...  
WO/2012/099477A1
The invention relates to methods of localising biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S' for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to ...  
WO/2012/011106A1
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...  
WO/2010/139411A3
The invention relates to 17ß-alkyl-17α-oxy-estratrienes of formula (I), methods for producing the same, the use of the 17ß-alkyl-17α-oxy-estratrienes for producing medicaments, and pharmaceutical preparations containing said compounds.  
WO/2010/136940A1
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...  
WO/2010/071772A2
The present invention relates to methods for synthesizing preferred membrane-binding elements, preferably cholesterylamine derivatives, including 3-amino-5-cholestene (3-cholesterylamine) and related 3-halides through i-steroid and retro...  
WO/2009/108388A8
Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a met...  
WO/2009/108388A3
Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a met...  
WO/2009/108388A2
Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a met...  
WO/2008/133387A1
The present invention relates to a novel acyclic triterpenoid compound and a pharmaceutical composition comprising an Alpinia katsumadai extract or acyclic triterpenoid compound isolated therefrom. The Alpinia katsumadai extract or acycl...  
WO/2007/147713A1
New aminoalkoxyimino derivatives at position 3 of substituted B- homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, ...  
WO/2007/099548A2
11 β-hydroxyandrosta-4-ene-3-one, compound of formula (I), and physiologically acceptable salt thereof; wherein R4 represents moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C)...  
WO/2007/099548A3
11 β-hydroxyandrosta-4-ene-3-one, compound of formula (I), and physiologically acceptable salt thereof; wherein R4 represents moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C)...  
WO2006072600A8
The present invention is directed to compounds of formula (I): wherein R1 represents a 1,1-dimethylethyl group or a 1,1-dimethylpropyl group and physiologically acceptable solvates thereof, physiologically functional derivatives thereof,...  
WO/2007/057152A1
The present invention is directed to compounds of formula (I) wherein R1 represents C4-C7 branched chain alkyl, C3-C8 cycloalkyl optionally substituted by one or more groups independently selected from C1-C3 alkyl and methoxy, C4-C6 cycl...  
WO2005077968B1
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...  
WO2005077968A8
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...  
WO2006072599A3
The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalkyl which optionally may be substituted with a C1-C4 alkyl group; R2 represents hydr...  
WO2006032885A3
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...  
WO/2006/072600A1
The present invention is directed to compounds of formula (I): wherein R1 represents a 1,1-dimethylethyl group or a 1,1-dimethylpropyl group and physiologically acceptable solvates thereof, physiologically functional derivatives thereof,...  
WO/2006/072599A2
The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalkyl which optionally may be substituted with a C1-C4 alkyl group; R2 represents hydr...  
WO/2006/032885A2
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...  
WO2005030120A3
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.  
WO/2005/077968A3
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...  
WO/2005/077968A2
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...  
WO/2005/030221A1
A drug exhibiting an excellent therapeutic efficacy for ageing macular degeneration. In particular, a therapeutic agent for ageing macular degeneration characterized in that a progesterone derivative of the general formula: (1) (wherein ...  
WO/2005/030120A2
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.  
WO2002042319A9
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.  
WO/2005/005451A1
A compound of formula (I): (I) wherein X represents O or S; R1 represents C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkylmethyl or C3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or...  
WO/2005/005452A1
A compound of formula (I): or a physiologically acceptable solvate thereof.  
WO2004039827A3
A compound of formula (I): whereinR1 represents C1-6 alkyl or C1-6 haloalkyl;X represents O or S;R2 represents C3-8 cycloalkyl which optionally may be substituted by one or more groups selected from C1-6 alkyl, oxo, or halogen n is an in...  
WO/2004/087731A1
A method for the conversion of steroidal 17β-carboxylic acids to c carbothioic acid and esters thereof such as fluticasone propionate.  
WO2004011663A3
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...  
WO/2004/039827A2
A compound of formula (I): whereinR1 represents C1-6 alkyl or C1-6 haloalkyl;X represents O or S;R2 represents C3-8 cycloalkyl which optionally may be substituted by one or more groups selected from C1-6 alkyl, oxo, or halogen n is an in...  
WO2004011663A9
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...  
WO2004001369A3
The present invention provides a convenient process for the preparation of S-fluoromethyl 6a, 9a-difluoro-11b-hydroxy-16a-methyl-17a-propionyloxy-3-oxoand rosta-1, 4-diene-17b-carbothioate, a compound of formula (1), comprising(a) treati...  
WO/2004/011663A2
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...  
WO/2004/009527A1
The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds ...  
WO2003047329A3
A method for producing a 6a-fluorinated corticosteroid or derivative thereof by reacting a17-hydroxy-21-ester epoxide of Formula (II) with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6a-fluorinate...  

Matches 1 - 50 out of 491